Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Psoriasis, Therapeutic response shortened
Clinical narrative: COVID-19/OMICRON; Psoriasis aggravated; Wearing off effect; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19/OMICRON), PSORIASIS (Psoriasis aggravated) and THERAPEUTIC RESPONSE SHORTENED (Wearing off effect) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and RISANKIZUMAB (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced COVID-19 (COVID-19/OMICRON), PSORIASIS (Psoriasis aggravated) and THERAPEUTIC RESPONSE SHORTENED (Wearing off effect). At the time of the report, COVID-19  had resolved, PSORIASIS (Psoriasis aggravated) had not resolved and THERAPEUTIC RESPONSE SHORTENED (Wearing off effect) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was provided. It was reported, since received injection patient skin was significantly improved.  Patient had covid, the only symptoms were the loss of smell and taste.  On 13-Dec-2021 patient had monoclonal antibodies. Patient had an outbreak and noticed more spots developing roughly about five to six spots.  Patient had spots that were accumulating on the lower leg area during a lapse in the administration frequency when started. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No treatment information was provided.  Company comment: This spontaneous case concerns an elderly female patient with no relevant medical history who experienced the unexpected non-serious AESI of COVID-19 which occurred unknown days after the administration of an unspecified dose of mRNA-1273 vaccine in COVID 19 vaccination series. The event had resolved. Further details regarding number and specifics of COVID 19 vaccines, therapy dates, concomitant medications, investigations, and treatment are not provided.  The benefit-risk relationship of mRNA-1273 is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 15-Feb-2022: Follow-up received event verbatim for COVID-19 updated,  outcome of event Psoriasis aggravated updated as not recovered/not resolved, I narrative updated. On 31-May-2022: Follow-up received outcome of event COVID-19 updated as recovered/resolved, I narrative updated.; Sender's Comments: This spontaneous case concerns an elderly female patient with no relevant medical history who experienced the unexpected non-serious AESI of COVID-19 which occurred unknown days after the administration of an unspecified dose of mRNA-1273 vaccine in COVID 19 vaccination series. The event had resolved. Further details regarding number and specifics of COVID 19 vaccines, therapy dates, concomitant medications, investigations, and treatment are not provided.  The benefit-risk relationship of mRNA-1273 is not affected by this report.